The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer [Thoracic Oncology]

Conclusion
Despite improved progression-free survival on therapy that did not contain erlotinib for KRAS mut+ patients and improved prognosis for mesenchymal tumors, better biomarker-driven treatment strategies are still needed.

Source: Journal of Clinical Oncology - October 11, 2016 Category: Cancer & Oncology Authors: Papadimitrakopoulou, Lee, Wistuba, Tsao, Fossella, Kalhor, Gupta, Byers, Izzo, Gettinger, Goldberg, Tang, Miller, Skoulidis, Gibbons, Shen, Wei, Diao, Peng, Wang, Tam, Coombes, Koo, Mauro, Rubin, Heymach, Hong, Herbst Tags: Translational Oncology, Chemotherapy, Lung Thoracic Oncology Source Type: research